22.11.2010 • News

New Deal Structure for Genzyme?

U.S. biotechnology firm Genzyme, which is fending off an $18.5 billion hostile takeover bid from France's Sanofi-Aventis, is considering a new deal structure that Sanofi has said it would be open to, The Wall Street Journal reported on Sunday.

Genzyme has been holding internal discussions to consider the use of a contingent value right (CVR), which give shareholders more value if the acquired company hits benchmarks, the Journal reported, citing people familiar with the matter.

This particular CVR would likely be tied to the performance of Genzyme drug Campath, an experimental drug for multiple sclerosis that has already been approved for cancer.

Sanofi has called Genzyme's projection of up to $3.5 billion in peak sales for Campath unrealistic. Genzyme has dismissed Sanofi's $69 per share bid as too low. Sanofi and Genzyme could not be immediately reached for comment.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read